TABLE 1.
Summary of evaluated single and double drug combinations
| Model | Status | Cocktail |
|---|---|---|
| aiPSC‐WT | Pluripotent uninfected | Fibroblast + OKSM + Dox |
| aiLUNG (ie, wild type) | Differentiated uninfected | aiPSC + NKX‐2.1 + WNT5a + LUNG medium |
| aiLUNG + SARS‐CoV‐2 | Differentiated infected and untreated | aiLUNG + initial viremia + active TMPRSS2 |
| aiLUNG + SARS‐CoV‐2 + HCQ | Differentiated infected and treated (1 drug) | aiLUNG + viremia + active TMPRSS2 + HCQ |
| aiLUNG + SARS‐CoV‐2 + RdRPi | Differentiated infected and treated (1 drug) | aiLUNG + viremia + active TMPRSS2 + RdRP inhibitor |
| aiLUNG + SARS‐CoV‐2 + PLproi | Differentiated infected and treated (1 drug) | aiLUNG + viremia + active TMPRSS2 + PLpro inhibitor |
| aiLUNG + SARS‐CoV‐2 + 3CLproi | Differentiated infected and treated (1 drug) | aiLUNG + viremia + active TMPRSS2 + 3CLpro inhibitor |
| aiLUNG + SARS‐CoV‐2 + HCQ + RdRPi | Differentiated infected and treated (2 drug) | aiLUNG + viremia + active TMPRSS2 + HCQ + RdRP inhibitor |
| aiLUNG + SARS‐CoV‐2 + HCQ + PLproi | Differentiated infected and treated (2 drug) | aiLUNG + viremia + active TMPRSS2 + HCQ + PLpro inhibitor |
| aiLUNG + SARS‐CoV‐2 + HCQ + 3CLproi | Differentiated infected and treated (2 drug) | aiLUNG + viremia + active TMPRSS2 + HCQ + 3CLpro inhibitor |
| aiLUNG + SARS‐CoV‐2 + RdRPi + PLproi | Differentiated infected and treated (2 drug) | aiLUNG + viremia + active TMPRSS2 + RdRP inhibitor + PLpro inhibitor |
| aiLUNG + SARS‐CoV‐2 + RdRPi + 3CLproi | Differentiated infected and treated (2 drug) | aiLUNG + viremia + active TMPRSS2 + RdRP inhibitor + 3CLpro inhibitor |
| aiLUNG + SARS‐CoV‐2 + PLproi + 3CLproi | Differentiated infected and treated (2 drug) | aiLUNG + viremia + active TMPRSS2 + PLpro inhibitor + 3CLpro inhibitor |
Abbreviations: 3CLpro, 3 chymotrypsin Like protease; aiLUNG‐COVID‐19, aiLUNG + SARS‐CoV‐2; Dox, doxycycline; HCQ, hydroxychloroquine; OKSM, OCT4, KLF4, SOX2, cMYC; PLpro, papain like protease; RdRP, RNA dependent RNA polymerase.